CD8A and myeloid sarcoma: There were no significant differences in the counts of lymphocytes, CD4+T cells, and CD8+T cells and the percentages of CD4+T cells between the MS patients at pre-treatment and HCs, while the percentage of CD8+T cells was significantly lower in MS patients than in HCs (p<0.05) (Fig 1A–1C).